Sign in
Active, not recruitingPhase 2/3

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Key facts

Who runs it
Denali Therapeutics Inc.
Where
Chapel Hill, Chicago, Cincinnati, Hackensack, Houston, Oakland, Philadelphia, and Salt Lake City, United StatesSee the 8 sitesAlso in 13 other countries, 23 sites
Status
Active, not recruiting
Phase
Phase 2/3
People taking part
65 people enrolled
Started
21 Jul 2022
Expected to end
Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • tividenofusp alfa
  • idursulfase
Record updated
9 September 2026

Who can take part

Age
2 years to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants aged ≥2 to <6 years (Cohort A) or ≥6 to <26 years (Cohort B)
  • Confirmed diagnosis of MPS II (for Cohort A, nMPS II; for Cohort B, nnMPS II)
  • Have no history of treatment with enzyme replacement therapy (ERT) OR not have received continuous ERT for 4 months prior to screening OR be on maintenance ERT and have tolerated idursulfase for a minimum of 4 months prior to screening

Who cannot take part

  • Previously received an iduronate 2-sulfatase (IDS) gene therapy or stem cell therapy
  • Received any CNS-targeted MPS ERT within 6 months prior to screening
  • Participated in any other investigational drug study or used an investigational drug within 60 days prior to screening or intend to receive another investigational drug during the study
  • Have a documented mutation of other genes or genetic diagnosis accounting for developmental delay
  • Have a contraindication for lumbar punctures and/or magnetic resonance imaging (MRI)

Where in United States

Also in 13 other countries, 23 sites

  • UNC Children's Research InstituteChapel Hill, United States
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United States
  • Cincinnati Children's Hospital Medical CenterCincinnati, United States
  • Hackensack University Medical CenterHackensack, United States
  • The University of Texas Medical School at HoustonHouston, United States
  • UCSF Benioff Children's Hospital OaklandOakland, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • University of Utah - PPDSSalt Lake City, United States

About the trial

What the trial wants to find out

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).

Read full original descriptionShow less

Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.

The 3 groups in the trial

  • Cohort A: Participants with nMPS IITreatment being tested

    Treatment: tividenofusp alfa and idursulfase

  • Cohort B: Participants with nnMPS IITreatment being tested

    Treatment: tividenofusp alfa and idursulfase

  • Open-label Treatment PhaseTreatment being tested

    Participants who meet pre-specified criteria may receive DNL310 or idursulfase

    Treatment: tividenofusp alfa and idursulfase

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II
Record updated
9 September 2026